123 related articles for article (PubMed ID: 27841077)
1. Preclinical evaluation of the potential for cytochrome P450 inhibition and induction of the selective ALK inhibitor, alectinib.
Sekiguchi N; Nagao S; Takanashi K; Kato M; Kaneko A; Morita K; Shindoh H; Ishigai M
Xenobiotica; 2017 Dec; 47(12):1042-1051. PubMed ID: 27841077
[TBL] [Abstract][Full Text] [Related]
2. Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.
Morcos PN; Cleary Y; Guerini E; Dall G; Bogman K; De Petris L; Viteri S; Bordogna W; Yu L; Martin-Facklam M; Phipps A
Clin Pharmacol Drug Dev; 2017 May; 6(3):280-291. PubMed ID: 27545757
[TBL] [Abstract][Full Text] [Related]
3. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of curculigoside on human liver cytochrome P450 enzymes.
Lang J; Li W; Zhao J; Wang K; Chen D
Xenobiotica; 2017 Oct; 47(10):849-855. PubMed ID: 27819189
[TBL] [Abstract][Full Text] [Related]
5. In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes.
Nakagawa T; Fowler S; Takanashi K; Youdim K; Yamauchi T; Kawashima K; Sato-Nakai M; Yu L; Ishigai M
Xenobiotica; 2018 Jun; 48(6):546-554. PubMed ID: 28657423
[TBL] [Abstract][Full Text] [Related]
6. Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance.
Hofman J; Sorf A; Vagiannis D; Sucha S; Novotna E; Kammerer S; Küpper JH; Ceckova M; Staud F
Drug Metab Dispos; 2019 Jul; 47(7):699-709. PubMed ID: 31068367
[TBL] [Abstract][Full Text] [Related]
7. Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.
Cleary Y; Gertz M; Morcos PN; Yu L; Youdim K; Phipps A; Fowler S; Parrott N
Clin Pharmacol Ther; 2018 Sep; 104(3):505-514. PubMed ID: 29226313
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
[TBL] [Abstract][Full Text] [Related]
9. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
Kodama T; Hasegawa M; Takanashi K; Sakurai Y; Kondoh O; Sakamoto H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1023-8. PubMed ID: 25205428
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice.
He W; Wu JJ; Ning J; Hou J; Xin H; He YQ; Ge GB; Xu W
Toxicol In Vitro; 2015 Oct; 29(7):1569-76. PubMed ID: 26100226
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the in vitro and in vivo metabolic pathway and cytochrome P450 inhibition/induction profile of Huperzine A.
Lin PP; Li XN; Yuan F; Chen WL; Yang MJ; Xu HR
Biochem Biophys Res Commun; 2016 Nov; 480(2):248-253. PubMed ID: 27751854
[TBL] [Abstract][Full Text] [Related]
13. In vitro inhibition of human liver cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes by rose bengal: system-dependent effects on inhibitory potential.
Kazmi F; Haupt LJ; Horkman JR; Smith BD; Buckley DB; Wachter EA; Singer JM
Xenobiotica; 2014 Jul; 44(7):606-14. PubMed ID: 24405273
[TBL] [Abstract][Full Text] [Related]
14. In vitro Inhibitory Effects of Cynaroside on Human Liver Cytochrome P450 Enzymes.
Wang L; Ma X; Wang J; Li C
Pharmacology; 2019; 104(5-6):296-302. PubMed ID: 31587003
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.
Hong H; Su H; Ma L; Yao M; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2011 Sep; 39(9):1658-67. PubMed ID: 21673131
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the
Giri P; Gupta L; Singh S; Patel N; Srinivas NR; Srivastva BK; Desai RC; Patel PR
Xenobiotica; 2019 Oct; 49(10):1164-1172. PubMed ID: 30488748
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory Effects of Triptolide on Human Liver Cytochrome P450 Enzymes and P-Glycoprotein.
Zhang H; Ya G; Rui H
Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):89-98. PubMed ID: 26874845
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450-mediated metabolism of the synthetic cannabinoids UR-144 and XLR-11.
Nielsen LM; Holm NB; Olsen L; Linnet K
Drug Test Anal; 2016 Aug; 8(8):792-800. PubMed ID: 26360322
[TBL] [Abstract][Full Text] [Related]
19. Alectinib for treatment of ALK-positive non-small-cell lung cancer.
Avrillon V; Pérol M
Future Oncol; 2017 Feb; 13(4):321-335. PubMed ID: 27780368
[TBL] [Abstract][Full Text] [Related]
20.
Li J; Wen H; Gao Z
Xenobiotica; 2020 Feb; 50(2):231-236. PubMed ID: 31020909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
